● Recruiting

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Condition: Alzheimer's Disease · Sponsor: Eisai Co., Ltd.

PhaseN/A

Planned participants5000

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

This description comes directly from the study's public registry record.

Talk to the study team

Eisai Inquiry Service. · eisai-chiken_hotline@hhc.eisai.co.jp

Always discuss trial participation with your own doctor first.

Locations (3)

Eisai trial site 2	Hiroshima, Japan	Recruiting
Eisai trial site 3	Kyoto, Japan	Recruiting
Eisai trial site 1	Tokyo, Japan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06322667